Emergent BioSolutions (EBS) Retained Earnings (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Retained Earnings of -$153.0 million for Q1 2026, down 2408.2% year-over-year from $6.6 million in Q1 2025, and down 1940.0% quarter-over-quarter from -$7.5 million in Q4 2025.
Emergent BioSolutions (EBS) Retained Earnings (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Retained Earnings history runs 17 years deep, the most recent figure standing at -$153.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 2408.2% year-over-year to -$153.0 million; the TTM figure through Mar 2026 stood at -$153.0 million (down 2408.2% YoY), while the FY2025 annual figure was -$7.5 million, up 96.47% from the prior year.
- Retained Earnings for Q1 2026 stood at -$153.0 million, down from -$7.5 million in the prior quarter.
- The five-year high for Retained Earnings was $924.4 million in Q3 2024, with the low at -$212.4 million in Q4 2024.
- The 5-year median for Retained Earnings is -$5.5 million (2024), against an average of $286.3 million.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 35653.85% in 2024, then tumbled 2408.2% in 2026.
- Emergent BioSolutions' Retained Earnings stood at $738.7 million in 2022, then rose by 22.43% to $904.4 million in 2023, then plunged by 123.49% to -$212.4 million in 2024, then soared by 96.47% to -$7.5 million in 2025, then sank by 1940.0% to -$153.0 million in 2026.
- Business Quant data shows EBS's Retained Earnings at -$153.0 million in Q1 2026, -$7.5 million in Q4 2025, and -$105.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 951.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 951.80 Mn |
| Mar 31, 2026 | -153.00 Mn |
| Dec 31, 2025 | -7.50 Mn |
| Sep 30, 2025 | -105.20 Mn |
| Jun 30, 2025 | -8.10 Mn |
| Mar 31, 2025 | -6.10 Mn |
| Dec 31, 2024 | -212.40 Mn |
| Sep 30, 2024 | 924.40 Mn |
| Jun 30, 2024 | -5.50 Mn |
| Mar 31, 2024 | -12.80 Mn |
| Dec 31, 2023 | 904.40 Mn |
| Sep 30, 2023 | -2.60 Mn |
| Jun 30, 2023 | 289.70 Mn |
| Mar 31, 2023 | 878.20 Mn |
| Dec 31, 2022 | 738.70 Mn |
| Sep 30, 2022 | 805.70 Mn |
| Jun 30, 2022 | 849.20 Mn |
| Mar 31, 2022 | -9.30 Mn |
| Dec 31, 2021 | -16.10 Mn |
| Sep 30, 2021 | 768.50 Mn |